Intensity-modulated versus conventional radiation therapy for oropharyngeal carcinoma: Long-term dysphagia and tumor control outcomes

Head and Neck

Volumn 36, Issue 4, 2014, Pages 492-498

  McBride, Sean M ^a,b   Parambi, Ron J ^a   Jang, Joanne W ^a,b   Goldsmith, Tessa ^a   Busse, Paul M ^a   Chan, Annie W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

intensity modulated radiation therapy; oropharynx; stricture; survival; toxicity; xerostomia

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; PACLITAXEL;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CERVICAL ESOPHAGEAL STRICTURE; CHEMORADIOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CONVENTIONAL RADIOTHERAPY; DYSPHAGIA; ESOPHAGOSCOPY; ESOPHAGUS STENOSIS; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION INJURY; STOMACH TUBE; TREATMENT OUTCOME; WART VIRUS; XEROSTOMIA;

INTENSITY-MODULATED RADIATION THERAPY; OROPHARYNX; STRICTURE; SURVIVAL; TOXICITY; XEROSTOMIA;

CARCINOMA; DEGLUTITION DISORDERS; ESOPHAGEAL STENOSIS; FEMALE; GASTROSTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OROPHARYNGEAL NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; XEROSTOMIA;

EID: 84896127602     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23319     Document Type: Article

References (20)

1. Guadagnolo BA, Liu CC, Cormier JN, Du XL,. Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population-based cohort. Cancer 2010; 116: 3505-3512.
2. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-136.
3. Roe JW, Carding PN, Dwivedi RC, et al. Swallowing outcomes following intensity modulated radiation therapy (IMRT) for head & neck cancer-a systematic review. Oral Oncol 2010; 46: 727-733.
4. Huang K, Xia P, Chuang C, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer 2008; 113: 497-507.
5. Gray RJ,. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
6. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
7. Fine JP, Gray RJ,. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
8. Cox DR,. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972; 34: 187-220.
9. Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA,. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 2009; 74: 1-8.
10. Salama JK, Stenson KM, List MA, et al. Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2008; 134: 1060-1065.
11. Rusthoven KE, Raben D, Ballonoff A, Kane M, Song JI, Chen C,. Effect of radiation techniques in treatment of oropharynx cancer. Laryngoscope 2008; 118: 635-639.
12. Caudell JJ, Schaner PE, Meredith RF, et al. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 73: 410-415.
13. Wang JJ, Goldsmith TA, Holman AS, Cianchetti M, Chan AW,. Pharyngoesophageal stricture after treatment for head and neck cancer. Head Neck 2011; 34: 967-973.
14. Caudell JJ, Burnett OL III, Schaner PE, Bonner JA, Duan J,. Comparison of methods to reduce dose to swallowing-related structures in head and neck cancer. Int J Radiat Oncol Biol Phys 2010; 77: 462-467.
15. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
16. Nichols AC, Finkelstein DM, Faquin WC, et al. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Cancer Res 2010; 16: 2138-2146.
17. Staffurth J,; Radiotherapy Development Board. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 2010; 22: 643-657.
18. Lee NY, de Arruda FF, Puri DR, et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 966-974.
19. Rothschild S, Studer G, Seifert B, et al. PET/CT staging followed by intensity-modulated radiotherapy (IMRT) improves treatment outcome of locally advanced pharyngeal carcinoma: a matched-pair comparison. Radiat Oncol 2007; 2: 22.
20. Hodge CW, Bentzen SM, Wong G, et al. Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. Int J Radiat Oncol Biol Phys 2007; 69: 1032-1041.